Related Experiment Video
Updated: May 16, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with
Ja Yoon Heo1, Chung Lee2, Heesun Shin3
1Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Background:
Docetaxel remains a standard treatment for metastatic castration-resistant prostate cancer (mCRPC), yet reliable prognostic markers are lacking. TP53 and RB1, key tumor suppressor genes regulating cell-cycle control and genomic stability, have been linked to aggressive disease and lineage plasticity in advanced prostate cancer. We evaluated the prognostic impact of TP53 and/or RB1 alterations in mCRPC patients treated with docetaxel.
Methods:
We retrospectively analyzed 125 mCRPC patients treated with docetaxel. Genetic alterations were assessed using the TruSight Oncology 500 v2 panel. Progression-free survival (PFS) and overall survival (OS) were analyzed according to TP53 and RB1 alteration status.
Results:
TP53 alterations were present in 45 patients (36.0%) and RB1 alterations in 16 (12.8%). Patients with alterations in either TP53 or RB1 had significantly shorter OS (median OS = 18.10 vs. 32.23 months; HR = 1.83, 95% CI = 1.19-2.84; p = .006). Co-altered patients showed the poorest OS (median OS = 11.40 months; HR = 5.09, 95% CI = 1.97-13.19; p < .001). PFS was also shorter in patients with TP53 or RB1 alterations.
Conclusion:
TP53 and RB1 alterations, particularly TP53/RB1 co-alteration, are associated with poor prognosis in mCRPC treated with docetaxel.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drugs that Stabilize Microtubules

